NewTimeSpace News: On 24 August 2026, BAIYUNSHAN PH (00874.HK) announced that the Norepinephrine Bitartrate Injection (1ml:2mg) of its wholly-owned subsidiary Mingxing Pharmaceutical has passed the generic drug quality and efficacy consistency evaluation, with domestic sales of the drug amounting to RMB 768.58 million in 2025 and R&D investment of approximately RMB 1.2557 million (unaudited).
NewTimeSpace News: On August 24, 2026, XPENG-W (09868.HK) weakened in the afternoon. As of 14:04, the stock traded at HK$47.18, down 1.91%.
NewTimeSpace (newtimespace.com) News, August 24, 2026—the chip theme pulled back sharply, and HUA HONG GRACE (01347.HK) weakened amid volatility. As of 13:23, the company's quote stood at HKD 108.500, down 5.49%.
NewTimeSpace (newtimespace.com) News, August 24, 2026—the robot theme lost momentum, yet MIDEA GROUP (00300.HK) swung higher. As of 13:16, the company's quote stood at HKD 98.000, up 1.14%.
NewTimeSpace News: AIM Vaccine announced on August 24 that the marketing authorization application for its self-developed high-potency human diploid rabies vaccine adopting an optimized production process has been submitted to the National Medical Products Administration.
On August 21, 2026, the three major Hong Kong stock indices continued to strengthen — the Hang Seng Index rose 1.21%, the Hang Seng TECH Index gained 1.40%, and the Hang Seng China Enterprises Index advanced 1.01%. AI concept themes strengthened collectively on the day, while leading tech and internet stocks were mixed.In the large-model segment, the "twin leaders" surged — MINIMAX-W (00100.HK) rose 11.86%, Z.AI (02513.HK) gained 10.36%, with TENCENT, KUAISHOU-W and BIDU-SW following the gains. ALIBABA-W (09988.HK) fell 2.54% post-earnings, and MEITUAN-W dropped 0.99%.
NewTimeSpace News: On 21 August 2026, SHANDONG XINHUA (00719.HK) announced that it has obtained the drug registration certificate for dapagliflozin tablets (10mg and 5mg), indicated for type 2 diabetes and heart failure.
NewTimeSpace News: On 21 August 2026, LEADS BIOLABS-B (09887.HK) announced that the NDA for Virexin, its self-developed PD-L1/4-1BB bispecific antibody, as monotherapy for advanced pretreated EP-NEC has been accepted by the NMPA, making it the world's first such antibody submitted for approval.
NewTimeSpace News: On August 21, 2026, BIDU-SW (09888.HK) edged higher in the afternoon session. As of 14:14, the stock was quoted at HK$93.10, up 1.03%.
NewTimeSpace (newtimespace.com) News, On August 21, 2026, the chip theme rebounded, while ASMPT (00522.HK) traded weaker amid fluctuations. As of 13:31, the company quoted HKD 158.500, down 1.43%.
NewTimeSpace (newtimespace.com) News, On August 21, 2026, the robot theme moved with volatility, while XIAOMI-W (01810.HK) strengthened. As of 13:15, the company quoted HKD 28.840, up 3.89%.
NewTimeSpace News: On 20 August 2026, LUYE PHARMA (02186.HK) voluntarily announced that its therapeutic mRNA vaccine LY01620 is about to initiate a Phase II clinical trial in China for patients with HPV16-positive HSIL; the Phase I study showed an HPV viral clearance rate of nearly 90% and histological improvement approaching standard surgical levels, with the treatment being non-invasive and not affecting fertility.
NewTimeSpace News: On 21 August 2026, CSTONE PHARMA-B (02616.HK) voluntarily announced that the IND of CS5007, an EGFR/HER3 bispecific ADC, has been fast-tracked and approved by the NMPA in 23 working days; its global multi-center Phase I trial was initiated in Australia in June 2026 with the first patient enrolled, and approximately 310 patients are expected to be enrolled.
NewTimeSpace News: On 21 August 2026, LONGBIO-B (01779.HK) voluntarily announced that the BLA of LP-003 for seasonal allergic rhinitis has been accepted by the NMPA; LP-003 is a novel anti-IgE antibody targeting multiple allergic diseases, and its IND application for peanut allergy was previously approved by the US FDA.
NewTimeSpace News: On 20 August 2026, HENGRUI PHARMA (01276.HK) disclosed that its subsidiary received the clinical trial approval notice for SHR-7012 injection, indicated for cutaneous lupus erythematosus; no drug targeting the same target has been approved domestically or internationally, with cumulative R&D investment of approximately RMB 25.5 million.
On August 20, 2026, the Hang Seng Index rose 0.80%, the Hang Seng TECH Index gained 0.39%, and the Hang Seng China Enterprises Index advanced 0.90%.AI concept stocks showed a divergent performance on the day: the large-model segment moved unevenly, the AI chip sector was mixed, and the intelligent-driving segment mostly strengthened.In the large-model segment, the "twin leaders" MINIMAX-W rose 6.16%; the company announced the launch of its multimodal creation Agent workbench, MiniMax Design. Z.AI rose 1.09%, with BIDU-SW, ALIBABA-W and others following the gains. MEITUAN-W fell 1.38%, and KUAISHOU-W tumbled more than 10% post-earnings.
